Golestan University of Medical Sciences Repository

Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016

Cowan, A.J. and Allen, C. and Barac, A. and Basaleem, H. and Bensenor, I. and Curado, M.P. and Foreman, K. and Gupta, R. and Harvey, J. and Dean Hosgood, H. and Jakovljevic, M. and Khader, Y. and Linn, S. and Lad, D. and Mantovani, L. and Nong, V.M. and Mokdad, A. and Naghavi, M. and Postma, M. and Roshandel, G. and Shackelford, K. and Sisay, M. and Nguyen, C.T. and Tran, T.T. and Xuan, B.T. and Ukwaja, K.N. and Vollset, S.E. and Weiderpass, E. and Libby, E.N. and Fitzmaurice, C. (2018) Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. JAMA Oncology, 4 (9). pp. 1221-1227.

Full text not available from this repository.


INTRODUCTION Multiplemyeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden ofMMis needed to help direct health policy, resource allocation, research, and patient care. OBJECTIVE To describe the burden ofMMand the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016. DESIGN AND SETTING We report incidence, mortality, and disability-Adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study. Data sources include vital registration system, cancer registry, drug availability, and survey data for stem cell transplant rates.We analyzed the contribution of aging, population growth, and changes in incidence rates to the overall change in incident cases from 1990 to 2016 globally, by sociodemographic index (SDI) and by region.We collected data on approval of lenalidomide and bortezomib worldwide. MAIN OUTCOMES AND MEASURES Multiplemyeloma mortality; incidence; years lived with disabilities; years of life lost; and DALYs by age, sex, country, and year. RESULTS Worldwide in 2016 there were 138 509 (95uncertainty interval UI, 121 000-155 480) incident cases ofMMwith an age-standardized incidence rate (ASIR) of 2.1 per 100 000 persons (95%UI, 1.8-2.3). Incident cases from 1990 to 2016 increased by 126% globally and by 106%to 192%for all SDI quintiles. The 3 world regions with the highest ASIR ofMMwere Australasia, North America, andWestern Europe. Multiplemyeloma caused 2.1 million (95%UI, 1.9-2.3 million) DALYs globally in 2016. Stem cell transplantation is routinely available in higher-income countries but is lacking in sub-Saharan Africa and parts of the Middle East. In 2016, lenalidomide and bortezomib had been approved in 73 and 103 countries, respectively. CONCLUSIONS AND RELEVANCE Incidence ofMMis highly variable among countries but has increased uniformly since 1990, with the largest increase in middle and low-middle SDI countries. Access to effective care is very limited in many countries of low socioeconomic development, particularly in sub-Saharan Africa. Global health policy priorities forMMare to improve diagnostic and treatment capacity in low and middle income countries and to ensure affordability of effective medications for every patient. Research priorities are to elucidate underlying etiological factors explaining the heterogeneity inmyeloma incidence. © 2018 American Medical Association. All rights reserved.

Item Type: Article
Additional Information: cited By 2
Uncontrolled Keywords: bortezomib; lenalidomide, adolescent; adult; Africa south of the Sahara; aged; Australia and New Zealand; cancer incidence; cancer mortality; China; Conference Paper; demography; disability-adjusted life year; drug approval; female; Germany; global disease burden; health care availability; high income country; human; Israel; major clinical study; male; Middle East; multiple myeloma; Netherlands; North America; North Korea; sociodemographic index; stem cell transplantation; Sweden; Taiwan; Western Europe
Subjects: سیستم های خونی و لنفاوی WH
بهداشت عمومی WA
مقالات نمایه شده محققین دانشگاه در سایت ,Web of Science ,Scopus
Depositing User: GOUMS
Date Deposited: 23 Dec 2018 10:42
Last Modified: 23 Dec 2018 10:42
URI: http://eprints.goums.ac.ir/id/eprint/9742

Actions (login required)

View Item View Item